TACSTD2 and pancreatic neoplasm: In human T cell-reconstituted immunodeficient mice, this anti-Trop2 ProTriTAC displayed potent antitumor effects across various xenograft models, such as HPAFII (pancreatic cancer), CAL27 (head and neck cancer), and HCC70 (breast cancer), with complete tumor regression at doses as low as 30 μg/kg.